| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000011483 |
| Receipt No. | R000013440 |
| Official scientific title of the study | Aripiprazole versus duloxetine in combination with mirtazapine for treatment-resistant,major deressive disorder: a rater-masked,randomized trial. |
| Date of disclosure of the study information | 2013/08/14 |
| Last modified on | 2017/02/15 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Aripiprazole versus duloxetine in combination with mirtazapine for treatment-resistant,major deressive disorder: a rater-masked,randomized trial. | |
| Title of the study (Brief title) | Aripiprazole versus duloxetine in combination with mirtazapine for treatment-resistant,major deressive disorder:randomized trial. | |
| Region |
|
|
| Condition | ||
| Condition | major depressive disorder | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The aim of study is to compare clinical efficacy and tolerability of aripiprazole versus duloxetine as combination treatment with mirtazapine in patients with resistant major depressive disorder. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Hamilton Raing Scale for Depression |
| Key secondary outcomes | discontimuation rate, remission rate, adverse events |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Duloxetine | |
| Interventions/Control_2 | Aripiprazole | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | DSM-4-TR:MDD
Patients with treatment-resistant MDD: HAMD17>15:sufficient dose SSRI (ESC>15mg,PAR>30mg,SER>75mg,FLU>112,5mg) for more than 2 weeks. After that, the patients have no respose (HAMD17>15)to MIR 30mg/day for more than 2 weeks |
|||
| Key exclusion criteria | Patient with the following disorders (based on DSM-IV-TR criteria): psychotic disorders, pervasive developmental disorders, bipolar disorder, obsessive-compulsive disorder, Axis-2 disorder.
Patients with substance abuse or dependence (excluding nicotine and caffeine) meeting DSM-IV-TR criteria Patients taking MAO inhibitors with in14 days (or Patients treated with MAO inhibitors within 14 days) Patients taking pimozide Patients with allergies to escitalopram, duloxetine and aripiprazole Patients with QT interval prolongation Patients treated with ECT within the previous 6 months Patients having severe physical disease Patients who are pregnant or may become pregnant Patients at significant risk of suicide (having a score >3 on HAM-D item 11) Patients who had made suicide attempt within the past year |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Nakao Iwata |
| Organization | Fujita Health University School of Medicine |
| Division name | Department of Psychiatry |
| Address | 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi. 470-1192. Japan |
| TEL | 0562-93-9250 |
| nakao@fujita-hu.ac.jp | |
| Public contact | |
| Name of contact person | Taro Kishi |
| Organization | Fujita Health University School of Medicine |
| Division name | Department of Psychiatry |
| Address | 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi. 470-1192. Japan |
| TEL | 0562-93-9250 |
| Homepage URL | |
| tarok@fujita-hu.ac.jp | |
| Sponsor | |
| Institute | Department of Psychiatry, Fujita Health University School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Department of Psychiatry, Fujita Health University School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000013440 |